T

Tongling Jieya Biologic Technology Co Ltd
SZSE:301108

Watchlist Manager
Tongling Jieya Biologic Technology Co Ltd
SZSE:301108
Watchlist
Price: 26.76 CNY -5.31% Market Closed
Market Cap: 2.2B CNY
Have any thoughts about
Tongling Jieya Biologic Technology Co Ltd?
Write Note

Tongling Jieya Biologic Technology Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tongling Jieya Biologic Technology Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
T
Tongling Jieya Biologic Technology Co Ltd
SZSE:301108
Cost of Revenue
-ÂĄ439.7m
CAGR 3-Years
3%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Hengan International Group Company Ltd
HKEX:1044
Cost of Revenue
-ÂĄ15.2B
CAGR 3-Years
-6%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
Proya Cosmetics Co Ltd
SSE:603605
Cost of Revenue
-ÂĄ3.3B
CAGR 3-Years
-28%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
Cost of Revenue
-ÂĄ1.5B
CAGR 3-Years
-31%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
By-health Co Ltd
SZSE:300146
Cost of Revenue
-ÂĄ2.9B
CAGR 3-Years
-9%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
G
Giant Biogene Holding Co Ltd
HKEX:2367
Cost of Revenue
-ÂĄ577m
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tongling Jieya Biologic Technology Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Consumer products

Tongling Jieya Biologic Technology Co., Ltd. engages in the research and development, production, and sale of wet wipes. The company is headquartered in Tongling, Anhui and currently employs 798 full-time employees. The company went IPO on 2021-12-03. The firm's main businesses are the research and development, production and sales of sanitary products. The firm's wet wipes products include baby series, adult functional series, antibacterial disinfection series, household cleaning series, medical care series and pet cleaning series. The firm is also engaged in the production of facial masks.

Intrinsic Value
22.97 CNY
Overvaluation 14%
Intrinsic Value
Price
T

See Also

What is Tongling Jieya Biologic Technology Co Ltd's Cost of Revenue?
Cost of Revenue
-439.7m CNY

Based on the financial report for Dec 31, 2023, Tongling Jieya Biologic Technology Co Ltd's Cost of Revenue amounts to -439.7m CNY.

What is Tongling Jieya Biologic Technology Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-19%

Over the last year, the Cost of Revenue growth was 4%. The average annual Cost of Revenue growth rates for Tongling Jieya Biologic Technology Co Ltd have been 3% over the past three years , -19% over the past five years .

Back to Top